Catherine Shaffer

1 week ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Johnson & Johnson CEO Joaquin Duato believes that Rybrevant (amivantamab) plus Lazcluze (lazertinib) will become the new standard of care in first-line EGFR-mutated advanced non-small cell lung cancer after the combination extended overall survival by more than a year, compared to AstraZeneca's Tagrisso (osimertinib) in a clinical trial.

2 weeks ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Following its acquisition of TigaTx earlier this week, Epsilogen is mulling its options for new biomarker-driven cancer therapeutics by leveraging new capabilities across three antibody isotypes. Epsilogen was founded in 2017 in London to advance antibodies for cancer based on immunoglobulin E (IgE). This focus set it apart from other companies developing antibody therapies, which have overwhelmingly built their drugs using immunoglobulin G (IgG).

1 month ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Cure51 hopes to put a dent in cancer mortality by studying the mechanisms of exceptional survival in patients with very aggressive cancers such as those that affect the pancreas and brain. In those cancers, five-year survival rates can be abysmally low, but research has traditionally focused on how to extend survival for patients who progress quickly or don't respond to treatment, rather than the factors contributing to survival.

1 month ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Optellum and Volpara Health teamed up this week to market artificial intelligence (AI)-driven cancer detection tools to hospitals in the US, pairing Optellum's lung cancer capabilities with Volpara's suite of tools for analyzing breast imaging. Oxford, England-based Optellum develops AI-driven solutions for lung cancer. Its Virtual Nodule Clinic analyzes imaging data to determine the likelihood that a lung nodule is cancerous.

1 month ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Memorial Sloan Kettering Cancer Center has built a data infrastructure that now represents 140,000 tumor samples and 100,000 cancer patients and is using it to train machine learning models that can effectively pull critical information from unstructured electronic health records using natural language processing (NLP). While the models are still in early development, MSK researchers hope to harness the database in the future to make individualized cancer treatment decisions.